KINTOR PHARMA-B

9939
1.3304.32% ( -0.060 )
Delay Closed: Nov 16, 16:08:00

Overview

KINTOR PHARMA-B (9939)

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its...

Open
1.420
High
1.420
Low
1.310
Prev. Close
1.390
Volume
747.00K
Turnover
999.74K
Avg Price
1.338
Bid/Ask Ratio
74.03%
Amplitude
7.91%
52wk High
4.700
Volume Ratio
1.33
Turnover Ratio
0.15%
52wk Low
1.210
HK Mkt Cap
663.22M
Market CapHKD
663.22M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.445
EPSDynamic
-0.350
EPSStatic
--
BVPS
0.25
P/B
5.27
HK Shares
498.66M
Dividend YieldTTM
--
DividendTTM
--
Shares
498.66M
Min lot size
500
Currency
HKD

KINTOR PHARMA-B Analyst Rating

View more

Forecast & Rating

Oct 16, 2024
Price forecast
HK$14.14963.21%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Kintor Pharmaceutical opened low and rallied, closing up 3.5%. The morning session started at HKD 1.970 and trended upward, accelerating in the afternoon to hit an intraday high of HKD 2.100 before settling at HKD 2.060 on turnover of approximately HKD 2.47 million. The rally was primarily fueled by positive news flow: the company previously announced its GT20029 gel achieved the primary endpoint in a Phase II clinical trial for acne in China, a milestone viewed as a pipeline breakthrough; additionally, insider confidence was signaled by shareholder KT International Investment Limited's recent share purchases at HKD 1.93 and HKD 2.20. Financially, Q4 2025 revenue surged 458% YoY to HKD 14.84 million, but net loss widened 45.7% to HKD 64.96 million, with EPS of -HKD 0.1396 and a net margin of -437.6%. While the stock closed below its session high of HKD 2.100, the persistent loss expansion underscores the gap between pipeline optimism and near-term profitability.

News